Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...
In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...
Pfizer's CEO, Albert Bourla, Ph.D., has attempted to downplay the investor threat. At the J.P. Morgan Healthcare Conference ...
Few CEOs know the double-edged nature of dealing with US President Donald Trump as viscerally as Pfizer’s Albert Bourla. In his first term, Trump championed the $18 billion Operation Warp Speed ...
Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.
Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...
3don MSN
CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results